

1 **Germline mutations in young-onset sporadic pituitary macroadenomas: a multigene panel**  
2 **analysis**

3

4 Leonor M. Gaspar<sup>1</sup>, Catarina I. Gonçalves<sup>1</sup>, Ema L. Nobre<sup>2</sup>, Fernando Fonseca<sup>3</sup>, Cláudia Amaral<sup>4</sup>,  
5 João S. Duarte<sup>5</sup>, Luísa Raimundo<sup>6</sup>, Catarina Saraiva<sup>5</sup>, Luísa Cortez<sup>3</sup>, Olinda Marques<sup>7</sup>, Manuel C.  
6 Lemos<sup>1\*</sup>

7

8 <sup>1</sup> CICS-UBI, Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal

9 <sup>2</sup> Serviço de Endocrinologia, Diabetes e Metabolismo, Hospital de Santa Maria, Unidade Local de  
10 Saúde Santa Maria, Lisboa, Portugal

11 <sup>3</sup> Serviço de Endocrinologia, Hospital de Curry Cabral, Unidade Local de Saúde São José, Lisboa,  
12 Portugal

13 <sup>4</sup> Serviço de Endocrinologia, Hospital de Santo António, Centro Hospitalar Universitário do Porto,  
14 Porto, Portugal

15 <sup>5</sup> Serviço de Endocrinologia, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisboa,  
16 Portugal

17 <sup>6</sup> Serviço de Endocrinologia e Diabetes, Hospital Garcia de Orta, Almada, Portugal

18 <sup>7</sup> Serviço de Endocrinologia, Hospital de Braga, Braga, Portugal

19

20 \* Corresponding author:

21 Manuel C. Lemos

22 CICS-UBI, Health Sciences Research Centre

23 University of Beira Interior

24 6200-506 Covilhã, Portugal

25 Email: [mclemos@fcsaude.ubi.pt](mailto:mclemos@fcsaude.ubi.pt)

26 **ORCID ID: 0009-0001-0326-8006** has not been certified by peer review and should not be used to guide clinical practice.

27

28 Short title: Germline mutations in pituitary adenomas

29

30 Keywords: Pituitary adenoma; Genetics; Mutation

31

32 Word count 2701 (excluding abstract, references, table, figure legend, and supplemental

33 material).

34

35 **Abstract**

36

37 **Objective:** Mutations in several genes have been associated with familial forms of pituitary  
38 adenomas. Sporadic pituitary adenomas (i.e. with no family history or coexistent endocrine  
39 tumours) are also occasionally found to result from germline mutations in these genes,  
40 especially in young patients with larger tumours. The aim of this study was to determine the  
41 frequency of germline mutations in patients with young-onset sporadic pituitary  
42 macroadenomas.

43 **Methods:** A cohort of 225 Portuguese patients with sporadic pituitary macroadenomas  
44 diagnosed before the age of 40 years was studied by whole exome sequencing (WES) followed  
45 by the analysis of a virtual panel of 29 genes that have been associated with predisposition to  
46 pituitary adenomas.

47 **Results:** Pathogenic and likely pathogenic variants were identified in 16 (7.1%) of patients. The  
48 affected genes were *AIP* (n=4), *PMS2* (n=4), *MEN1* (n=2), *VHL* (n=2), *CDH23* (n=1), *MSH2* (n=1),  
49 *SDHB* (n=1), and *TP53* (n=1). In patients diagnosed under the ages of 30 and 18 years, the  
50 frequency of mutations increased to 9.0% and 12.0%, respectively.

51 **Conclusion:** This is so far the largest multigene analysis of patients with young-onset sporadic  
52 pituitary macroadenomas. We confirmed the *AIP* as the most frequently involved gene, but also  
53 uncovered rarer genetic causes of pituitary adenomas, including the first independent  
54 confirmation of a role of the *CDH23* gene. The results may contribute to a better understanding  
55 of the genetic landscape of these tumours and help to decide which genes to include in the  
56 genetic screening of patients with young-onset pituitary macroadenomas.

57

## 58 Introduction

59 Most pituitary adenomas occur sporadically and are often attributed to acquired somatic and  
60 epigenetic mutations (1). However, a subset of cases arises within a familial context, either as  
61 part of syndromic diseases or as familial isolated pituitary adenomas (FIPA), which are caused  
62 by pathogenic germline mutations (2). Tumours within familial settings tend to be more  
63 aggressive, manifesting at a younger age, with larger sizes, increased invasiveness, and  
64 resistance to standard treatments (3). An expanding list of genes, including *AIP*, *CABLES1*,  
65 *CDH23*, *CDKN1A*, *CDKN1B*, *CDKN2B*, *CDKN2C*, *DICER1*, *GNAS*, *GPR101*, *MAX*, *MEN1*, *MLH1*,  
66 *MSH2*, *MSH6*, *NF1*, *PMS2*, *PRKACA*, *PRKACB*, *PRKAR1A*, *RET*, *SDHA*, *SDHAF2*, *SDHB*, *SDHC*, *SDHD*,  
67 *TP53*, *USP8*, and *VHL*, has been identified with germline or mosaic mutations predisposing  
68 individuals to pituitary adenomas (4-6) . Identifying these genetic alterations is not only crucial  
69 for accurate diagnosis and personalized treatment, but also provides valuable insights into the  
70 molecular pathways disrupted in these tumours (7).

71 While sporadic cases traditionally lack a clear hereditary component, several studies have shown  
72 that a variable proportion of these cases harbour germline mutations (8). The most extensively  
73 studied gene is *AIP*, which was first associated with FIPA (9), but later found to be mutated in  
74 many apparently sporadic cases, particularly among patients of younger ages and with larger  
75 tumours (10).

76 We recently screened a cohort of patients diagnosed with young-onset sporadic pituitary  
77 macroadenomas for *AIP* mutations (11). This revealed the presence of *AIP* mutations in 1.8%,  
78 3.4% and 5.0% of patients diagnosed under the ages of 40, 30 and 18 years, respectively (11).  
79 Building upon this, we have now employed next-generation sequencing to expand the genetic  
80 screening to all genes with germline mutations that have so far been associated with familial  
81 isolated or syndromic pituitary adenomas.

82

## 83 **Materials and Methods**

### 84 **Subjects**

85 This was a follow-up study of a Portuguese multicentre cohort that had been previously studied  
86 by conventional (Sanger) sequencing of the *AIP* gene (11). A total of 225 patients were available  
87 for this study. Inclusion criteria were patients with macroadenomas (tumour greater diameter  $\geq$   
88 1 cm) diagnosed under the age of 40 years. Exclusion criteria were patients with a family history  
89 of pituitary adenomas (i.e. affected first or second degree family member) or with evidence of  
90 a syndromic form of pituitary adenoma. Mean age ( $\pm$  standard deviation) at diagnosis was 29.1  
91  $\pm$  7.3 years, 122 patients were under 30 years at diagnosis, and 25 patients were under 18 years  
92 at diagnosis. Gender distribution was 116 (51.6%) females and 109 (48.4%) males. Tumour  
93 classification was based on histological examination or, in the case of prolactinomas, by clinical,  
94 hormonal and radiological examination. Eighty-one (36.0%) patients had prolactinomas, 62  
95 (27.6%) had somatotrophinomas, 37 (16.4%) had non-functioning pituitary adenomas, 16 (7.1%)  
96 had mixed-secreting pituitary adenomas, 15 (6.7%) had corticotrophinomas, seven (3.1%) had  
97 gonadotrophinomas, one (0.4%) had a thyrotrophinoma, and six (2.7%) had adenomas with  
98 undetermined histology. The control population comprised 298 Portuguese individuals (50  
99 healthy blood donors and 248 patients with unrelated disorders). The study was approved by  
100 the Ethics Committee of the Faculty of Health Sciences, University of Beira Interior (Ref: CE-UBI-  
101 Pj-2018-027 and CE-FCS-2011-003) and written informed consent was obtained from all  
102 subjects.

103

### 104 **Whole exome sequencing (WES) and virtual gene panel**

105 Genomic deoxyribonucleic acid (DNA) was extracted from the peripheral blood leukocytes of  
106 each patient and used for WES analysis according to previously described methods (12). A virtual  
107 gene panel was created, consisting of 29 genes in which germline or mosaic mutations have  
108 been reported in patients with familial isolated or syndromic pituitary adenomas (4-6), namely  
109 *AIP* (NM\_003977.3), *CABLES1* (NM\_001100619.2), *CDH23* (NM\_022124.5), *CDKN1A*  
110 (NM\_078467.3), *CDKN1B* (NM\_004064.4), *CDKN2B* (NM\_004936.4), *CDKN2C* (NM\_001262.3),  
111 *DICER1* (NM\_177438.3), *GNAS* (NM\_000516.7), *GPR101* (NM\_054021.1), *MAX* (NM\_002382),  
112 *MEN1* (NM\_130799.2), *MLH1* (NM\_000249.4), *MSH2* (NM\_000251.3), *MSH6* (NM\_000179.3),  
113 *NF1* (NM\_000267.3), *PMS2* (NM\_000535.7), *PRKACA* (NM\_002730.4), *PRKACB* (NM\_182948.4),  
114 *PRKAR1A* (NM\_002734.5), *RET* (NM\_020975.4), *SDHA* (NM\_004168.3), *SDHAF2* (NM\_017841.2),

115 *SDHB* (NM\_003000.3), *SDHC* (NM\_003001.5), *SDHD* (NM\_003002.3), *TP53* (NM\_000546.6),  
116 *USP8* (NM\_005154.5), and *VHL* (NM\_000551.3).

117

### 118 **Interpretation of genetic variants**

119 Genetic variants were filtered according to the following cumulative criteria: 1) Location in one  
120 of the 29 genes previously implicated in pituitary adenomas; 2) Location in coding transcripts  
121 used by the Human Genome Mutation Database (HGMD) (13); 3) Location in coding exons or up  
122 to ten nucleotides adjacent to the coding exons; and 4) Population allele frequency less than  
123 0.001 in the Genome Aggregation Database (gnomAD) and 1000 Genomes database (14). The  
124 variants selected by these criteria were classified as benign (B), likely benign (LB), variant of  
125 uncertain significance (VUS), likely pathogenic (LP) or pathogenic (P), according to American  
126 College of Medical Genetics and Genomics (ACMG) criteria (15) and ClinGen recommendations  
127 (16), using a web-based variant interpretation tool (Franklin by Genoox, reference hg19,  
128 <https://franklin.genoox.com/>, accessed on 30 March 2024). Filtered variants were screened in  
129 an in-house database of 298 Portuguese control individuals to assess the possibility of variants  
130 being population-specific common polymorphisms.

131

### 132 **Validation of genetic variants by Sanger sequencing**

133 Variants classified as pathogenic and likely pathogenic were confirmed by conventional Sanger  
134 sequencing using a semi-automated DNA sequencer (STAB VIDA, Caparica, Portugal; and ABI  
135 3730XL, Applied Biosystems; Thermo Fisher Scientific, Waltham, MA, USA).

136

## 137 **Results**

### 138 **Rare sequence variants identified in the 29 analysed genes**

139 A total of 154 (141 different) rare sequence variants (population allele frequency <0.001) were  
140 identified in 114 of the 225 patients. These variants were found in 25 of the 29 analysed genes  
141 and included three pathogenic, 13 likely pathogenic (11 different), 63 VUS (56 different), 64  
142 likely benign (61 different) and 11 benign (10 different) (Supplemental Data 1). All rare sequence  
143 variants were identified in the heterozygous state.

144

### 145 **Pathogenic and likely pathogenic variants**

146 Pathogenic and likely pathogenic variants were identified in 16 (7.1%) patients with young-onset  
147 sporadic pituitary macroadenomas. These consisted of four *AIP* gene mutations (previously  
148 reported by us (11)) (p.Ser53ThrfsTer36, p.Arg81Ter, p.Leu115TrpfsTer41, and p.Glu246Ter),  
149 four *PMS2* mutations (three patients with p.Asn335Ser, and one with p.Asp486GlufsTer109),  
150 two *MEN1* mutations (p.Trp183Ter, and p.Arg314\_Asp315del), two *VHL* mutations  
151 (p.Lys196Glu, and p.Glu52Ter), one *CDH23* mutation (p.Glu2520Lys), one *MSH2* mutation  
152 (p.Arg524His), one *SDHB* mutation (p.Ile127Leu), and one *TP53* mutation (p.Arg282Gln) (Table  
153 1 and Figure 1).

154

### 155 **Prevalence of mutations according to age of diagnosis**

156 The prevalence of mutations was higher in patients with younger ages at diagnosis. The  
157 prevalence of mutations in patients diagnosed up until the age of 40, 30 and 18 years was 7.1%  
158 (16/225), 9.0% (11/122), and 12.0% (3/25), respectively.

159

### 160 **Clinical characteristics of patients with mutations**

161 The clinical characteristics of the 16 patients with identified mutations are presented in Table 1.  
162 Patients had no personal history of additional tumours or other syndromic features at the time  
163 of inclusion in the study. However, two patients with *MEN1* mutations were found to have  
164 hyperparathyroidism during or after undertaking the genetic studies.

165

## 166 Discussion

167 Our analysis of 225 patients with young-onset sporadic pituitary macroadenomas showed that  
168 16 (7.1%) patients had germline mutations in genes that are associated with familial forms of  
169 pituitary adenomas. These mutations involved the *AIP* (1.8% of patients), *PMS2* (1.8%), *MEN1*  
170 (0.9%), *VHL* (0.9%), *CDH23* (0.4%), *MSH2* (0.4%), *SDHB* (0.4%), and *TP53* (0.4%) genes.

171 The *AIP* gene is associated with FIPA (9), but has also been extensively studied in patients with  
172 sporadic pituitary adenomas. The prevalence of *AIP* germline mutations in patients with  
173 sporadic pituitary macroadenomas under the age of 40 has been reported to vary from 0% to  
174 18% (11), depending of the country of origin, clinical characteristics of the cohort, and criteria  
175 used for the classification of genetic variants. We found four (1.8%) patients with *AIP* mutations,  
176 which were frameshift (p.Ser53ThrfsTer36, and p.Leu115TrpfsTer41) and nonsense (p.Arg81Ter,  
177 and p.Glu246Ter) mutations expected to lead to a premature stop codon and to the formation  
178 of a shorter protein or to nonsense-mediated decay (17). These *AIP* mutations were all found in  
179 patients with GH-secreting adenomas, in agreement with the higher prevalence of *AIP*  
180 mutations in this tumour type (18). These results confirm the results of our previous Sanger  
181 sequencing of the *AIP* gene in this cohort of patients (11).

182 The *PMS2* gene is associated with Lynch syndrome (19), which is characterised by the occurrence  
183 of a variety of tumours that include colorectal, endometrial, ovarian and gastric cancers (20).  
184 Although some cases of aggressive pituitary tumours have been reported in patients with Lynch  
185 syndrome (21-23), the prevalence of *PMS2* mutations in sporadic pituitary adenomas has never  
186 been reported before. We found four (1.8%) patients with *PMS2* mutations, with no other  
187 apparent manifestations of Lynch syndrome. These consisted of a previously reported (24)  
188 missense (p.Asn335Ser) mutation that was identified in three unrelated patients, diagnosed  
189 with a somatotrophinoma, prolactinoma and non-functioning pituitary adenoma, and a novel  
190 frameshift (p.Asp486GlufsTer109) mutation in a patient with a prolactinoma. Thus, our study  
191 suggests that the *PMS2* gene has a more important role in pituitary tumorigenesis than  
192 previously acknowledged.

193 The *MEN1* gene is associated with the multiple endocrine neoplasia type 1 (MEN1) syndrome,  
194 which is characterised by the occurrence of parathyroid, pancreatic and pituitary tumours (25,  
195 26). *MEN1* mutations are occasionally found in patients with pituitary adenomas without other  
196 MEN1 manifestations. A previous study identified *MEN1* mutations in 3.4% of patients with  
197 sporadic pituitary macroadenomas diagnosed before the age of 30 (27). Our study found two  
198 (0.9%) patients with *MEN1* mutations, which consisted of a previously reported (26) nonsense



199 mutation (p.Trp183Ter) and a novel in-frame deletion (p.Arg314\_Asp315del). Both patients had  
200 mixed GH-secreting adenomas. It is interesting to note that although there were no other  
201 apparent manifestations of the MEN1 syndrome at the time of the diagnosis of the pituitary  
202 adenoma, both patients were eventually found to have hyperparathyroidism during or after  
203 undertaking the genetic studies.

204 The *VHL* gene is associated with the Von Hippel–Lindau (VHL) syndrome, which is characterised  
205 by tumours in several organs, such as retinal and central nervous system haemangioblastomas,  
206 pheochromocytomas and clear-cell renal carcinomas (28). Pituitary adenomas have also been  
207 described in patients with the VHL syndrome (29). However, the prevalence of *VHL* mutations  
208 in sporadic pituitary adenomas has not been reported. We found two (0.9%) patients with *VHL*  
209 mutations, with no other apparent manifestations of the VHL syndrome. These consisted of a  
210 previously reported (30) nonsense (p.Glu52Ter) mutation in a patient with a prolactinoma and  
211 a previously reported (31) missense (p.Lys196Glu) mutation in a patient with a  
212 thyrotrophinoma. The latter mutation was previously reported in homozygosity in a patient with  
213 autosomal recessive congenital erythrocytosis, but with no evidence of the VHL syndrome (31).  
214 Therefore, it remains to be clarified if heterozygosity for this particular mutation, as found in our  
215 patient, can cause the VHL syndrome.

216 The *CDH23* gene is associated with the autosomal recessive Usher syndrome, which is  
217 characterized by congenital deafness (32). However, a study by Zhang et al. (33) demonstrated  
218 the presence of *CDH23* heterozygous mutations in 33% and 12% of familial and isolated pituitary  
219 adenomas, respectively. So far, these results have not been independently confirmed.  
220 Furthermore, there have been no reports of a higher incidence of pituitary adenomas in patients  
221 with Usher syndrome or in their heterozygous relatives. We found one (0.4%) patient with a GH-  
222 secreting adenoma and a previously reported (34) *CDH23* missense mutation (p.Glu2520Lys).  
223 Thus, our study represents the first independent confirmation of a role of *CDH23* in the  
224 development of pituitary adenomas.

225 The *MSH2* gene is also associated with Lynch syndrome (35, 36) and some affected patients have  
226 been reported to have aggressive pituitary adenomas (21-23). We found one (0.4%) patient with  
227 a previously reported (37) *MSH2* missense mutation (p.Arg524His), who had a prolactinoma with  
228 no other apparent manifestations of Lynch syndrome.

229 The *SDHB* gene is associated with paragangliomas and pheochromocytomas (38). Pituitary  
230 adenomas occasionally occur in association with these (3PA, Pheochromocytoma,  
231 Paraganglioma and Pituitary adenoma association) (39). However, the prevalence of *SDHB*

232 mutations in sporadic pituitary adenomas is unknown. A French study of 263 patients with  
233 sporadic pituitary adenomas revealed two mutations in the *SDHA* gene, one in the *SDHC* gene,  
234 but none in *SDHB* (40). We found one (0.4%) patient with a previously reported (41) *SDHB*  
235 missense mutation (p.Ile127Leu), who had a prolactinoma without any other syndromic  
236 manifestations.

237 The *TP53* gene is considered the most mutated tumour suppressor gene in human cancers (42).  
238 Germline mutations in this gene are associated with the Li-Fraumeni syndrome, which  
239 predisposes to soft tissue sarcomas, osteosarcoma, breast cancer, leukaemia, and  
240 adrenocortical carcinoma (43). The role of the *TP53* gene in pituitary adenomas is less clear. The  
241 *TP53* gene was included in our gene panel because a recent review (6) listed it as one of the  
242 genes in which germline mutations are implicated in pituitary adenomas. However, although  
243 somatic mutations in *TP53* have been reported in pituitary adenomas (1), we found no reports  
244 of germline mutations in patients with these tumours. Nevertheless, in our study, we found one  
245 (0.4%) patient with a previously reported (44) *TP53* germline missense mutation (p.Arg282Gln),  
246 who had a corticotrophinoma without any other syndromic manifestations. Thus, our study  
247 reports for the first time a *TP53* germline pathogenic mutation in a patient with a pituitary  
248 adenoma.

249 None of the patients included in our study had other coexistent tumours or syndromic features  
250 or family history that would raise the suspicion of a germline mutation. The unexpected  
251 identification of germline mutations in a subset of patients with sporadic tumours could have  
252 several explanations. First, family history was self-reported by the patients and may have been  
253 inaccurate or incomplete. Second, the lack of other affected family members could have been  
254 due to incomplete penetrance of the mutation or to a *de novo* mutation in the patient. Third,  
255 other syndromic manifestations could have been missed on clinical screening or absent due to  
256 variable expression of the mutation. Importantly, our identification of patients with germline  
257 mutations will improve their clinical management, allow the screening of additional syndromic  
258 manifestations, and allow the identification of additional affected family members that can be  
259 screened for the disorder (6).

260 Previous studies of sporadic pituitary adenomas have mainly focused on the *AIP* gene, as this is  
261 the most commonly mutated gene in such cases (8). Only three other studies performed gene  
262 panel analyses in patients with sporadic pituitary adenomas, but with a limited number of genes  
263 ( $\leq 9$ ) that did not include for example the *VHL*, *PMS2* or *CDH23* genes (40, 45, 46). Nevertheless,  
264 these studies were able to identify pathogenic variants in 3.8% to 10% of patients with young-  
265 onset sporadic pituitary adenomas.

266 In our study, we analysed the largest panel of genes so far in patients with sporadic pituitary  
267 adenomas. We confirmed the *AIP* as the most frequently involved gene in these patients, but  
268 also uncovered rarer genetic causes of pituitary adenomas. Altogether, germline mutations  
269 were present in 7.1% of our patients diagnosed with sporadic macroadenomas under the age of  
270 40 years. However, this proportion increased to 9.0% and 12.0%, in patients diagnosed under  
271 the ages of 30 and 18 years, respectively. This is in agreement with the general observation that  
272 tumours arising in younger ages are more likely to have a genetic cause.

273 The existence of subsets of patients at higher risk of harbouring germline mutations has led to  
274 recommendations for *AIP* and *MEN1* mutation testing in patients with pituitary macroadenomas  
275 diagnosed under the age of 30 (10, 27) or 40 years (47). However, there are currently no  
276 recommendations for additional genetic testing of sporadic pituitary adenomas that have been  
277 shown to be *AIP* and *MEN1* mutation-negative. Our study suggests that testing such patients for  
278 a wider gene panel may uncover further cases of genetically-determined pituitary adenomas.

279 Our study has some limitations. First, we did not look for copy number variants or mutations in  
280 non-coding genomic regions. Second, we did not look for mutations in other genes beyond those  
281 that have so far been associated with pituitary adenomas. Third, we found a large number of  
282 VUS, for which there is currently insufficient evidence for an association with the disorder, but  
283 that may need reclassification over time (48).

284 In conclusion, we found a prevalence of 7.1% germline mutations in patients with young-onset  
285 pituitary macroadenomas. These include mutations in the *AIP*, *MEN1*, *MSH2*, *PMS2*, *SDHB*, *TP53*  
286 and *VHL* genes and the first independent confirmation of a mutation in the *CDH23* gene. Our  
287 results may contribute to a better understanding of the genetic landscape of these tumours and  
288 help to decide which genes to include in the genetic screening of patients with young-onset  
289 pituitary macroadenomas.

290

291 **Supplementary data**

292 Supplementary data 1. Rare sequence variants identified in patients with young-onset sporadic  
293 pituitary macroadenomas.

294

295 **Conflict of interest**

296 The authors declare that there is no conflict of interest that could be perceived as prejudicing  
297 the impartiality of the research reported.

298

299 **Funding**

300 This research was funded by the Portuguese Foundation for Science and Technology (FCT,  
301 project grants PTDC/MEC-MET/29489/2017 and UIDB/00709/2020). LM Gaspar was the  
302 recipient of a PhD fellowship from FCT (SFRH/BD/147160/2019).

303

304 **Acknowledgements**

305 The authors are grateful to the following clinicians for collecting patient samples and clinical  
306 data: Ana Agapito (Lisboa), Ana Monteiro (Braga), Ana Palha (Lisboa), Bernardo Pereira (Ponta  
307 Delgada), Daniela Cavaco (Lisboa), Davide Carvalho (Porto), Hélder Simões (Lisboa), Henrique  
308 Luiz (Almada), Inês Barros (Braga), Inês Damásio (Lisboa), Isabel Inácio (Porto), Joana Pereira  
309 (Lisboa), João Anselmo (Ponta Delgada), Maria João Bugalho (Lisboa), Maria Manuel Silva  
310 (Porto), Maria Salomé (Lisboa), Mariana Barbosa (Braga), Rita Santos (Lisboa), Sara Donato  
311 (Lisboa), Sara Pinheiro (Lisboa), Sílvia Paredes (Braga), Teresa Martins (Coimbra), Teresa Rego  
312 (Lisboa), Tiago Silva (Lisboa), and Valeriano Leite (Lisboa).

313

314 **Data availability statement**

315 The data from this study are available from the corresponding author upon reasonable request.

316

317 **Author contribution statement**

318 LM Gaspar and CI Gonçalves contributed to the acquisition, analysis and curation of genetic data,  
319 and writing of the original draft of the manuscript. E Nobre, F Fonseca, C Amaral, J Sequeira  
320 Duarte, L Raimundo, C Saraiva, L Cortez, and O Marques contributed to the recruitment and

321 clinical studies of the patients. MC Lemos contributed to the conceptualization, funding  
322 acquisition, resources and supervision of the project. All authors contributed to reviewing and  
323 editing and approved the final version of the manuscript.

324

## 325   **References**

326

327   1.       Melmed S, Kaiser UB, Lopes MB, Bertherat J, Syro LV, Raverot G, et al. Clinical Biology of  
328   the Pituitary Adenoma. *Endocr Rev.* 2022;43(6):1003-37.

329   2.       De Sousa SMC, Lenders NF, Lamb LS, Inder WJ, McCormack A. Pituitary tumours:  
330   molecular and genetic aspects. *J Endocrinol.* 2023;257(3).

331   3.       Armeni E, Grossman A. The Spectrum of Familial Pituitary Neuroendocrine Tumors.  
332   *Endocr Pathol.* 2023;34(1):57-78.

333   4.       Vandeva S, Daly AF, Petrossians P, Zacharieva S, Beckers A. Somatic and germline  
334   mutations in the pathogenesis of pituitary adenomas. *European journal of endocrinology.*  
335   2019;181(6):R235-R54.

336   5.       Shen AJJ, King J, Scott H, Colman P, Yates CJ. Insights into pituitary tumorigenesis: from  
337   Sanger sequencing to next-generation sequencing and beyond. *Expert review of endocrinology*  
338   & *metabolism.* 2019;14(6):399-418.

339   6.       Coopmans EC, Korbonits M. Molecular genetic testing in the management of pituitary  
340   disease. *Clinical endocrinology.* 2022;97(4):424-35.

341   7.       Spada A, Mantovani G, Lania AG, Treppiedi D, Mangili F, Catalano R, et al. Pituitary  
342   Tumors: Genetic and Molecular Factors Underlying Pathogenesis and Clinical Behavior.  
343   *Neuroendocrinology.* 2022;112(1):15-33.

344   8.       Iacovazzo D, Hernandez-Ramirez LC, Korbonits M. Sporadic pituitary adenomas: the role  
345   of germline mutations and recommendations for genetic screening. *Expert review of*  
346   *endocrinology & metabolism.* 2017;12(2):143-53.

347   9.       Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, et al. Pituitary  
348   adenoma predisposition caused by germline mutations in the AIP gene. *Science (New York, NY).*  
349   2006;312(5777):1228-30.

350   10.      Tichomirowa MA, Barlier A, Daly AF, Jaffrain-Rea ML, Ronchi C, Yaneva M, et al. High  
351   prevalence of AIP gene mutations following focused screening in young patients with sporadic  
352   pituitary macroadenomas. *European journal of endocrinology.* 2011;165(4):509-15.

- 353 11. Gaspar LM, Goncalves CI, Saraiva C, Cortez L, Amaral C, Nobre E, et al. Low frequency of  
354 AIP mutations in patients with young-onset sporadic pituitary macroadenomas. *J Endocrinol*  
355 *Invest.* 2023;46(11):2299-307.
- 356 12. Goncalves CI, Carrico J, Bastos M, Lemos MC. Disorder of Sex Development Due to 17-  
357 Beta-Hydroxysteroid Dehydrogenase Type 3 Deficiency: A Case Report and Review of 70  
358 Different HSD17B3 Mutations Reported in 239 Patients. *Int J Mol Sci.* 2022;23(17):10026.
- 359 13. Stenson PD, Mort M, Ball EV, Evans K, Hayden M, Heywood S, et al. The Human Gene  
360 Mutation Database: towards a comprehensive repository of inherited mutation data for medical  
361 research, genetic diagnosis and next-generation sequencing studies. *Hum Genet.*  
362 2017;136(6):665-77.
- 363 14. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alfoldi J, Wang Q, et al. The mutational  
364 constraint spectrum quantified from variation in 141,456 humans. *Nature.* 2020;581(7809):434-  
365 43.
- 366 15. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines  
367 for the interpretation of sequence variants: a joint consensus recommendation of the American  
368 College of Medical Genetics and Genomics and the Association for Molecular Pathology.  
369 *Genetics in medicine : official journal of the American College of Medical Genetics.*  
370 2015;17(5):405-24.
- 371 16. Pejaver V, Byrne AB, Feng BJ, Pagel KA, Mooney SD, Karchin R, et al. Calibration of  
372 computational tools for missense variant pathogenicity classification and ClinGen  
373 recommendations for PP3/BP4 criteria. *Am J Hum Genet.* 2022;109(12):2163-77.
- 374 17. Karousis ED, Muhlemann O. The broader sense of nonsense. *Trends Biochem Sci.*  
375 2022;47(11):921-35.
- 376 18. Caimari F, Hernandez-Ramirez LC, Dang MN, Gabrovskaa P, Iacovazzo D, Stals K, et al. Risk  
377 category system to identify pituitary adenoma patients with AIP mutations. *Journal of medical*  
378 *genetics.* 2018;55(4):254-60.
- 379 19. Nicolaidis NC, Papadopoulos N, Liu B, Wei YF, Carter KC, Ruben SM, et al. Mutations of  
380 two PMS homologues in hereditary nonpolyposis colon cancer. *Nature.* 1994;371(6492):75-80.

- 381 20. Biller LH, Creedon SA, Klehm M, Yurgelun MB. Lynch Syndrome-Associated Cancers  
382 Beyond Colorectal Cancer. *Gastrointest Endosc Clin N Am.* 2022;32(1):75-93.
- 383 21. Teuber J, Reinhardt A, Reuss D, Hahnel S, Unterberg A, Beynon C. Aggressive pituitary  
384 adenoma in the context of Lynch syndrome: a case report and literature review on this rare  
385 coincidence. *Br J Neurosurg.* 2021:1-6.
- 386 22. Loughrey PB, Baker G, Herron B, Cooke S, Iacovazzo D, Lindsay JR, et al. Invasive ACTH-  
387 producing pituitary gland neoplasm secondary to MSH2 mutation. *Cancer Genet.* 2021;256-  
388 257:36-9.
- 389 23. Bengtsson D, Joost P, Aravidis C, Askmalm Stenmark M, Backman AS, Melin B, et al.  
390 Corticotroph Pituitary Carcinoma in a Patient With Lynch Syndrome (LS) and Pituitary Tumors in  
391 a Nationwide LS Cohort. *The Journal of clinical endocrinology and metabolism.*  
392 2017;102(11):3928-32.
- 393 24. Castéra L, Krieger S, Rousselin A, Legros A, Baumann JJ, Bruet O, et al. Next-generation  
394 sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture  
395 targeting multiple candidate genes. *Eur J Hum Genet.* 2014;22(11):1305-13.
- 396 25. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR,  
397 et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. *Science (New York,*  
398 *NY).* 1997;276(5311):404-7.
- 399 26. Lemmens I, Van de Ven WJ, Kas K, Zhang CX, Giraud S, Wautot V, et al. Identification of  
400 the multiple endocrine neoplasia type 1 (MEN1) gene. *The European Consortium on MEN1. Hum*  
401 *Mol Genet.* 1997;6(7):1177-83.
- 402 27. Cuny T, Pertuit M, Sahnoun-Fathallah M, Daly A, Occhi G, Odou MF, et al. Genetic  
403 analysis in young patients with sporadic pituitary macroadenomas: besides AIP don't forget  
404 MEN1 genetic analysis. *European journal of endocrinology.* 2013;168(4):533-41.
- 405 28. Latif F, Tory K, Gnarr J, Yao M, Duh FM, Orcutt ML, et al. Identification of the von Hippel-  
406 Lindau disease tumor suppressor gene. *Science (New York, NY).* 1993;260(5112):1317-20.
- 407 29. Denes J, Swords F, Rattenberry E, Stals K, Owens M, Cranston T, et al. Heterogeneous  
408 genetic background of the association of pheochromocytoma/paraganglioma and pituitary



- 409 adenoma: results from a large patient cohort. *The Journal of clinical endocrinology and*  
410 *metabolism*. 2015;100(3):E531-41.
- 411 30. Leonardi E, Martella M, Tosatto SC, Murgia A. Identification and in silico analysis of novel  
412 von Hippel-Lindau (VHL) gene variants from a large population. *Ann Hum Genet*. 2011;75(4):483-  
413 96.
- 414 31. Bento C, Almeida H, Maia TM, Relvas L, Oliveira AC, Rossi C, et al. Molecular study of  
415 congenital erythrocytosis in 70 unrelated patients revealed a potential causal mutation in less  
416 than half of the cases (Where is/are the missing gene(s)?). *Eur J Haematol*. 2013;91(4):361-8.
- 417 32. Bolz H, von Brederlow B, Ramirez A, Bryda EC, Kutsche K, Nothwang HG, et al. Mutation  
418 of CDH23, encoding a new member of the cadherin gene family, causes Usher syndrome type  
419 1D. *Nat Genet*. 2001;27(1):108-12.
- 420 33. Zhang Q, Peng C, Song J, Zhang Y, Chen J, Song Z, et al. Germline Mutations in CDH23,  
421 Encoding Cadherin-Related 23, Are Associated with Both Familial and Sporadic Pituitary  
422 Adenomas. *Am J Hum Genet*. 2017;100(5):817-23.
- 423 34. Cesca F, Bettella E, Polli R, Leonardi E, Aspromonte MC, Sicilian B, et al. Frequency of  
424 Usher gene mutations in non-syndromic hearing loss: higher variability of the Usher phenotype.  
425 *J Hum Genet*. 2020;65(10):855-64.
- 426 35. Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, et al. The human  
427 mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer.  
428 *Cell*. 1993;75(5):1027-38.
- 429 36. Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, Parsons R, et al. Mutations of a  
430 mutS homolog in hereditary nonpolyposis colorectal cancer. *Cell*. 1993;75(6):1215-25.
- 431 37. Paulo P, Maia S, Pinto C, Pinto P, Monteiro A, Peixoto A, et al. Targeted next generation  
432 sequencing identifies functionally deleterious germline mutations in novel genes in early-  
433 onset/familial prostate cancer. *PLoS Genet*. 2018;14(4):e1007355.
- 434 38. Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E, et al. Gene mutations in the  
435 succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and  
436 to familial paraganglioma. *Am J Hum Genet*. 2001;69(1):49-54.

- 437 39. O'Toole SM, Denes J, Robledo M, Stratakis CA, Korbonits M. 15 YEARS OF  
438 PARAGANGLIOMA: The association of pituitary adenomas and phaeochromocytomas or  
439 paragangliomas. *Endocr Relat Cancer*. 2015;22(4):T105-22.
- 440 40. Mougel G, Lagarde A, Albarel F, Essamet W, Luigi P, Mouly C, et al. Germinal defects of  
441 SDHx genes in patients with isolated pituitary adenoma. *European journal of endocrinology*.  
442 2020;183(4):369-79.
- 443 41. Ricketts CJ, Shuch B, Vocke CD, Metwalli AR, Bratslavsky G, Middleton L, et al. Succinate  
444 dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. *J Urol*.  
445 2012;188(6):2063-71.
- 446 42. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers.  
447 *Science (New York, NY)*. 1991;253(5015):49-53.
- 448 43. Malkin D, Li FP, Strong LC, Fraumeni JF, Jr., Nelson CE, Kim DH, et al. Germ line p53  
449 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. *Science*  
450 (New York, NY). 1990;250(4985):1233-8.
- 451 44. Chompret A, Brugieres L, Ronsin M, Gardes M, Dessarps-Freichay F, Abel A, et al. P53  
452 germline mutations in childhood cancers and cancer risk for carrier individuals. *Br J Cancer*.  
453 2000;82(12):1932-7.
- 454 45. De Sousa SMC, McCabe MJ, Wu K, Roscioli T, Gayevskiy V, Brook K, et al. Germline  
455 variants in familial pituitary tumour syndrome genes are common in young patients and families  
456 with additional endocrine tumours. *European journal of endocrinology*. 2017;176(5):635-44.
- 457 46. Martinez de LaPiscina I, Portillo Najera N, Rica I, Gaztambide S, Webb SM, Santos A, et  
458 al. Clinical and genetic characteristics in patients under 30 years with sporadic pituitary  
459 adenomas. *European journal of endocrinology*. 2021;185(4):485-96.
- 460 47. Cazabat L, Bouligand J, Salenave S, Bernier M, Gaillard S, Parker F, et al. Germline AIP  
461 mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center  
462 cohort of 443 patients. *The Journal of clinical endocrinology and metabolism*. 2012;97(4):E663-  
463 70.

464 48. Burke W, Parens E, Chung WK, Berger SM, Appelbaum PS. The Challenge of Genetic  
465 Variants of Uncertain Clinical Significance : A Narrative Review. *Ann Intern Med.*  
466 2022;175(7):994-1000.

467 49. Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S, et al. The role  
468 of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary  
469 adenomas. *The Journal of clinical endocrinology and metabolism.* 2008;93(6):2390-401.

470 50. Daly AF, Rostomyan L, Betea D, Bonneville JF, Villa C, Pellegata NS, et al. AIP-mutated  
471 acromegaly resistant to first-generation somatostatin analogs: long-term control with  
472 pasireotide LAR in two patients. *Endocrine connections.* 2019;8(4):367-77.

473

474 **Table 1.** Clinical and genetic characteristics of 16 patients with pathogenic (P) and likely pathogenic (LP) variants.

| Gene (transcript)             | Patient number (id) | Sex | Age at diagnosis (yr) | Type of adenoma (hormones produced) | Size of adenoma (mm) | Variant (nucleotide change, protein change) (a) | Effect              | Allele frequency in GnomAD | Allele frequency in Portuguese controls | ACMG classification (criteria) (b) | Previous report |
|-------------------------------|---------------------|-----|-----------------------|-------------------------------------|----------------------|---|---------------------|----------------------------|---|------------------------------------|-----------------|
| <i>AIP</i><br>(NM_003977.3)   | 1 (8215)            | F   | 19-30                 | GH                                  | 20                   | c.158_165delGCCGGGCT, p.Ser53ThrfsTer36         | Frameshift deletion | 0                          | 0                                       | LP (PVS1, PM2)                     | (11)*           |
|                               | 2 (7879)            | M   | 19-30                 | GH                                  | 26                   | c.241C>T, p.Arg81Ter                            | Nonsense            | 0                          | 0                                       | P (PVS1, PM2, PS4)                 | (49) (11)*      |
|                               | 3 (7329)            | M   | ≤18                   | GH/PRL                              | 14                   | c.343delC, p.Leu115TrpfsTer41                   | Frameshift deletion | 0                          | 0                                       | LP (PVS1, PM2)                     | (50) (11)*      |
|                               | 4 (7632)            | F   | 19-30                 | GH                                  | 28                   | c.736G>T, p.Glu246Ter                           | Nonsense            | 0                          | 0                                       | LP (PVS1, PM2)                     | (11)*           |
| <i>CDH23</i><br>(NM_022124.5) | 5 (7791)            | M   | 19-30                 | GH                                  | 25                   | c.7558G>A, p.Glu2520Lys                         | Missense            | 0                          | 0                                       | LP (PS4, PM2, PP3, PP5)            | (34)            |
| <i>MEN1</i><br>(NM_130799.2)  | 6 (7850)            | M   | 31-40                 | GH/PRL                              | 60                   | c.548G>A, p.Trp183Ter                           | Nonsense            | 0                          | 0                                       | P (PVS1, PS4, PP5, PM2)            | (26)            |
|                               | 7 (7971)            | F   | 19-30                 | GH/PRL/TSH                          | 40                   | c.940_945delCGGGAT, p.Arg314_Asp315del          | In-frame deletion   | 0                          | 0                                       | LP (PM1, PM2, PM4)                 | None            |
| <i>MSH2</i><br>(NM_000251.3)  | 8 (7642)            | F   | 19-30                 | PRL                                 | >10                  | c.1571G>A, p.Arg524His                          | Missense            | 0.000011                   | 0                                       | LP (PM2, PM5, PP3)                 | (37)            |
| <i>PMS2</i><br>(NM_000535.7)  | 9 (8072)            | M   | 31-40                 | GH                                  | >10                  | c.1004A>G, p.Asn335Ser                          | Missense            | 0.000273                   | 0                                       | LP (PP3, PM2, BP6)                 | (24)            |
|                               | 10 (8094)           | F   | 31-40                 | PRL                                 | 31                   | c.1004A>G, p.Asn335Ser                          | Missense            | 0.000273                   | 0                                       | LP (PP3, PM2, BP6)                 | (24)            |
|                               | 11 (8095)           | F   | 31-40                 | Non-functioning                     | 40                   | c.1004A>G, p.Asn335Ser                          | Missense            | 0.000273                   | 0                                       | LP (PP3, PM2, BP6)                 | (24)            |
|                               | 12 (7648)           | M   | 19-30                 | PRL                                 | >20                  | c.1458delC, p.Asp486GlufsTer109                 | Frameshift deletion | 0                          | 0                                       | LP (PVS1, PM2)                     | None            |
| <i>SDHB</i><br>(NM_003000.3)  | 13 (7887)           | F   | 19-30                 | PRL                                 | 20                   | c.379A>C, p.Ile127Leu                           | Missense            | 0.000004                   | 0                                       | LP (PM1, PM2, PM5, PP2, PP3)       | (41)            |

|                              |           |   |       |      |     |                       |          |          |   |   |      |
|------------------------------|-----------|---|-------|------|-----|-----------------------|----------|----------|---|---|------|
| <i>TP53</i><br>(NM_000546.6) | 14 (8079) | F | 31-40 | ACTH | 14  | c.845G>A, p.Arg282Gln | Missense | 0.000004 | 0 | LP (BS3, PM2,<br>PM5, PM1, PP3,<br>PP5) | (44) |
| <i>VHL</i><br>(NM_000551.3)  | 15 (6906) | F | ≤18   | PRL  | >10 | c.154G>T, p.Glu52Ter  | Nonsense | 0.000018 | 0 | LP (PVS1, PM2)                          | (30) |
|                              | 16 (7792) | M | ≤18   | TSH  | 10  | c.586A>G, p.Lys196Glu | Missense | 0        | 0 | P (PM1, PM2,<br>PM3, PP2, PP3,<br>PP5)  | (31) |

475 id, identification (anonymization code not known to anyone outside the research group); F, female; M, male; yr, years (presented as age range to protect patient privacy); FSH, follicle stimulating hormone; GH, growth  
476 hormone; LH, luteinizing hormone; PRL, prolactin; TSH, thyroid stimulating hormone; mm, millimeters; GnomAD, Genome Aggregation Database (v2.1.1). (a) All variants were heterozygous. (b) American College of  
477 Medical Genetics and Genomics (ACMG) classification of variants (P, pathogenic; LP, likely pathogenic) was based on the evidence for pathogenicity (very strong (PVS1), moderate (PM1–6), or supporting (PP1–5)).  
478 ACMG classifications were based on the web-based variant interpretation tool Franklin (Genoox Ltd, <https://franklin.genoox.com/>), accessed on 30 March 2024. \*Publication by the authors that included the same  
479 patient.

480

## Figure legend

**Figure 1.** Germline mutations identified in patients. The Sanger sequencing chromatograms are presented for each heterozygous mutation (indicated by an asterisk) and surrounding nucleotides.

